A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
for Non-squamous Non-small Cell Lung Cancer
Drug: Rilvegostomig
77 locations incl. Mobile
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06627647·Phase 3·Recruiting